✦ LIBER ✦

Platelet glycoprotein IIb/IIIa receptor antagonists and coronary artery disease

✍ Scribed by Phong Nguyen-Ho; Nasser M. Lakkis

Book ID: 107533599
Publisher: Current Science Inc.
Year: 2001
Tongue: English
Weight: 353 KB
Volume: 3
Category: Article
ISSN: 1523-3804
DOI: 10.1007/s11883-001-0050-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Oral glycoprotein IIb/IIIa antagonists i

Oral glycoprotein IIb/IIIa antagonists in coronary artery disease

✍ Derek P. Chew; Deepak L. Bhatt 📂 Article 📅 2001 🏛 Springer 🌐 English ⚖ 363 KB

Platelet glycoprotein IIb–IIIa receptor

Platelet glycoprotein IIb–IIIa receptor (GPIIb–IIIa) antagonists derived from amidinoindoles

✍ Daniel J. Sall; Ann E. Arfsten; Dennis R. Berry; Michael L. Denney; Cathy S. Har 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 352 KB

ChemInform Abstract: Platelet Glycoprote

ChemInform Abstract: Platelet Glycoprotein IIb/IIIa Receptor Antagonists Derived from Isoxazolidines.

✍ Pat N. Confalone; Fuqiang Jin; Shaker A. Mousa 📂 Article 📅 2010 🏛 John Wiley and Sons ⚖ 31 KB 👁 1 views

Platelet Glycoprotein IIb/IIIa Integrin

Platelet Glycoprotein IIb/IIIa Integrin Blockade in Coronary Artery Disease: Current State of the Art

✍ Huay-Cheem Tan; Robert A. Harrington; James E. Tcheng 📂 Article 📅 1997 🏛 Springer US 🌐 English ⚖ 277 KB

Emergency Coronary Artery Bypass Surgery

Emergency Coronary Artery Bypass Surgery in the Era of Glycoprotein IIb/IIIa Receptor Antagonist Use

✍ Jeffrey T. W. Pang; Stephen Fort; Anthony Delia Siega; Eric A. Cohen 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 656 KB

Platelet glycoprotein IIb/IIIa receptor

Platelet glycoprotein IIb/IIIa receptor blockade therapy for large coronary aneurysms and thrombi in Kawasaki disease

✍ Etheridge, Susan P. ;Tani, Lloyd Y. ;Minich, L. LuAnn ;Revenaugh, James R. 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 246 KB

A 4-month-old girl with Kawasaki disease, large coronary artery aneurysms, and coronary thrombi was treated with standard therapy followed by abciximab, a platelet glycoprotein IIb/IIIa antagonist, in addition to standard heparin and warfarin sodium anticoagulation and low-dose aspirin. She did not